Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

IV iron supplementation does not help with fatigue in regular blood donors

10 Sep 2020
Blood donation has a huge impact on saving many lives globally.

Intravenous (IV) iron supplementation may help boost concentrations of ferritin and haemoglobin in repeat blood donors with low iron stores, a recent study has found. However, there seems to be no impact on fatigue and general well-being.

The researchers enrolled blood donors who were randomly assigned to receive either a single IV dose of 800-mg iron carboxymaltose (n=203; mean age, 42.1±12.2 years; 46.3 percent female) or placebo (n=202; mean age, 42.2±12.3 years; 46.0 percent female). The primary study outcome was self-rated fatigue over the past 7 days. Secondary outcomes included well-being and blood parameters.

Six to 8 weeks after treatment, the self-rated mean fatigue score in the iron supplement group was 3.9±1.8, which was only marginally lower than that in the placebo arm (4.0±2.2; mean difference [MD], –0.04, 95 percent confidence interval [CI], –0.41 to 0.32; p=0.813).

However, researchers observed that at the same time point, serum ferritin increased significantly more in the iron supplement arm than in their placebo comparators (142.6±54.5 vs 28.6±61.3 µg/L; MD, 114.2 µg/L, 95 percent CI, 103.1–125.3; p<0.0001). The same was true for haemoglobin (142.7±10.9 vs 137.2±12.0 g/L; MD, 5.7 g/L; 95 percent CI, 4.3–7.2; p<0.001).

Patients who received IV iron supplementation also had a greater burden of adverse events (52 vs 29; p=0.019), though the proportion of participants who developed an adverse event was not significantly different between groups (20.2 percent vs 13.9 percent; p=0.09). No serious side effects or unexpected adverse reactions were reported.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.